Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the third quarter ended September 30, 2026, and provided a business update.
Covered in this story
Call it yourself
No calls on $TVRD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Tvardi Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.